Publication: Vincristine-induced peripheral neuropathy in children with malignancy and the effect of missed doses on treatment success
Loading...
Files
Date
2023-09-01
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Introduction: Recognizing the symptoms of vincristine-induced peripheral neuropathy (VIPN) earlier is
crucial to preventing the persistent neurological sequelae. The treatment of neuropathy is to discontinue the
drug, and the effect of a missed dose of vincristine on treatment success is unclear. This study aims to
evaluate VIPN in children with malignancy and the effect of skipping vincristine doses on the treatment
success of patients at a single center, retrospectively.
Methods: Medical records of the children with cancer who received vincristine in our institution between
2013 and 2020 were analyzed retrospectively.
Results: Vincristine neuropathy was found in 42 (7%) of 598 pediatric patients who received at least one dose
of vincristine during the study period. Neuropathy developed at a statistically significantly lower cumulative
dose in patients younger than seven years of age (p=0.04). The mean neuropathy duration of the cases was
8.5 months, and the findings of 40 (95.2%) cases improved. The mean cumulative dose was higher in patients
with diffuse nerve involvement. The missed dose of vincristine was lower in the cases in complete remission
compared to the other cases and higher doses of vincristine were missed in the stable disease group than in
the remission group (p=0.03).
Conclusion: VIPN can be encountered in less cumulative doses, mainly in the younger age group. Missed
doses of vincristine may affect treatment success, and more comprehensive studies are needed to show this
effect more clearly.
Description
Keywords
chemotherapy, children, cancer, peripheral neuropathy, vincristine
Citation
EKER N., ÖZTÜRK G., "Vincristine-Induced Peripheral Neuropathy in Children With Malignancy and the Effect of Missed Doses on Treatment Success", CUREUS, cilt.15, sa.9, 2023